noom glp 1 ingredients Launches Microdose GLP-1 Program, Including Medication and Microhabits Program mood balance Noom Partners With Liviniti on

2013 Jan;17(1):91-4

Retatrutide Safety Profile Nausea: 16-25% (dose-dependent) Diarrhea: 16-22% Heart rate increase at higher doses Discontinuation: 6-10% Limited long-term safety data Tirzepatide Safety Profile Nausea: 12-24% (dose-dependent) Diarrhea: 12-18% No significant heart rate changes Discontinuation: 5-7% Extensive Phase 3 and real-world data GI side effects were broadly similar between the two compounds in their respective trials, though direct comparison is limited by different study designs

Who Should Consider This Ingredient

We did a full webinar breaking down the topicmembers can access the recording on-demand , and download all the graphics from the session here

Improper storage: Storage that is too warm or too cold (frozen) reduces stability

Current clinical studies have focused on adults living with obesity, as well as adults who are overweight and have additional weightrelated health conditions